Deal Details
Follow-On Offering
Summary
Baird served as co-manager to Concert Pharmaceuticals, Inc. on this offering.
About
Concert Pharmaceuticals, Inc. (“Concert” or the “Company”) (NASDAQ: CNCE) recently completed a follow-on offering of 3,300,000 common shares at a price of $15.15 per share, generating gross proceeds of approximately $50 million. The Company intends to use the net proceeds from the offering for clinical development of its wholly owned programs, including D-ivacaftor, to advance and expand the research and preclinical development of additional product candidates and for working capital and other general corporate purposes.Concert is a clinical stage biopharmaceutical company that applies knowledge of deuterium chemistry to discover and develop novel small molecule drugs. The Company is headquartered in Lexington, Massachusetts.
For additional information about this transaction, please contact:
- Date
- April 2015
- Company
- Concert Pharmaceuticals, Inc.
- Transaction
- M&A
- Sectors
- Healthcare
- Target Geography
- North America
Share
